Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
  1. 4 Grant or award Director acquired 1,647 shares (grant or award)
  2. 4 Grant or award Director acquired 1,734 shares (grant or award)
  3. 4 Grant or award Chief Financial Officer acquired 370,343 shares (grant or award)
  4. 4 Shares withheld for taxes Chief Financial Officer gave up 22,725 shares (to pay taxes)
  5. 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.14 ($285,600)
  6. 3 Insider Initial Statement of Ownership
  7. 4 Grant or award Director acquired 105,037 shares (grant or award)
  8. 3 Insider Initial Statement of Ownership
  9. 4 Shares withheld for taxes Chief Medical Officer gave up 4,187 shares (to pay taxes)
  10. 4 Shares withheld for taxes Chief Financial Officer gave up 11,937 shares (to pay taxes)
  11. 4 Shares withheld for taxes President and COO gave up 14,286 shares (to pay taxes)
  12. 4 Shares withheld for taxes Chief Executive Officer gave up 26,023 shares (to pay taxes)
  13. 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.55 ($301,800)
  14. 4 Planned sale Director sold 11,447 shares at $7.64 ($87,457)
  15. 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $7.65 ($229,505)
  16. 4 Planned sale Director sold 11,447 shares at $6.72 ($76,926)
  17. 4 Planned sale President and COO sold 6,000 shares at $6.31 ($37,855)
  18. 4 Planned sale Director sold 11,447 shares at $6.67 ($76,326)
  19. 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $6.34 ($190,131)
  20. 4 Grant or award Director acquired 2,026 shares (grant or award)

Page 7 of 26 · 512 filings